Bivalirudin is a synthetic 20 amino acid peptide rationally designed based on structural studies of hirudin, a naturally occurring anticoagulant. Bivalirudin is sold under the brand name Angiomax and is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). It is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. Bivalirudin directly inhibits thrombin by binding simultaneously to its active catalytic site and its substrate recognition site.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P00734|||Q9UCA1 Gene ID: 2147.0 Gene Symbol: F2 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | ANGIOMAX Approved UseAngiomax™ is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). Angiomax is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. Launch Date2000 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. | 2004-01-15 |
|
| Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention. | 2003-11-01 |
|
| Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. | 2003-10-15 |
|
| Successful use of bivalirudin for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. | 2003-10 |
|
| Direct thrombin inhibitors for non-ST-segment elevation acute coronary syndromes: what, when, and where? | 2003-10 |
|
| Argatroban for off-pump coronary artery bypass surgery. | 2003-10 |
|
| Heparin-induced thrombocytopenia: pathophysiology and new treatment options. | 2003-09-19 |
|
| Bivalirudin in percutaneous coronary intervention. | 2003-09-15 |
|
| Heparin-induced thrombocytopenia and cardiac surgery. | 2003-08 |
|
| Contemporary use of antiplatelet therapies in percutaneous coronary interventions. | 2003-08 |
|
| Can bivalirudin and provisional GP IIb/IIIa blockade REPLACE heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention? | 2003-08 |
|
| Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention. | 2003-07-15 |
|
| Current anticoagulant therapy--unmet clinical needs. | 2003-07-15 |
|
| A 24-hour continuous infusion study of bivalirudin in the rat. | 2003-07-10 |
|
| Hirulog-like peptide reduces restenosis and expression of tissue factor and transforming growth factor-beta in carotid artery of atherosclerotic rabbits. | 2003-07 |
|
| Bivalirudin use in off-pump myocardial revascularization in patients with heparin-induced thrombocytopenia [corrected]. | 2003-07 |
|
| Bivalirudin in peripheral vascular interventions: a single center experience. | 2003-07 |
|
| Evolving role of bivalirudin in percutaneous coronary interventions; impact of the REPLACE-2 study. | 2003-06 |
|
| Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal and iliac interventions. | 2003-06 |
|
| Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations. | 2003-05-01 |
|
| Predicting the pharmacology of thrombin inhibitors. | 2003-05 |
|
| Direct thrombin inhibitors. | 2003-05 |
|
| In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant. | 2003-05 |
|
| An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study. | 2003-05 |
|
| Management of thrombotic and cardiovascular disorders in the new millenium. | 2003-04 |
|
| Anticoagulation in acute cardiac care in patients with chronic kidney disease. | 2003-04 |
|
| Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study. | 2003-03-15 |
|
| Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition. | 2003-03-15 |
|
| Bivalirudin (Angiomax) use during intracoronary brachytherapy may predispose to acute closure. | 2003-03 |
|
| The evolving role of direct thrombin inhibitors in acute coronary syndromes. | 2003-02-19 |
|
| Should bivalirudin replace heparin during percutaneous coronary interventions? | 2003-02-19 |
|
| Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. | 2003-02-19 |
|
| Reversing anticoagulants both old and new. | 2003-02-01 |
|
| Clinician update: direct thrombin inhibitors in acute coronary syndromes. | 2003-02 |
|
| Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass. | 2003-02 |
|
| Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. | 2003-01-22 |
|
| Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. | 2003-01 |
|
| Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood. | 2003 |
|
| Direct thrombin inhibitors in cardiac disease. | 2003 |
|
| Anticoagulation with bivalirudin during cardiopulmonary bypass in cardiac surgery. | 2002-12 |
|
| A Bayesian ordinal model for heterogeneity in a multi-centre myocardial infarction clinical trial. | 2002-10-30 |
|
| Gateways to clinical trials. | 2002-10 |
|
| Direct thrombin inhibitors in acute coronary syndromes. | 2002-08-10 |
|
| Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. | 2002-06 |
|
| Direct thrombin inhibitors. | 2002-05-01 |
|
| Current developments in antithrombotic therapy: the role of antithrombin agents. | 2002 |
|
| Current anticoagulation options in percutaneous intervention: designing patient-specific strategies. | 2002 |
|
| Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction. | 2002 |
|
| Development and current applications of thrombin-specific inhibitors. | 2001-06 |
|
| Thrombin-specific inhibition by and slow cleavage of hirulog-1. | 1992-05-01 |
Patents
Sample Use Guides
The recommended dosage of Angiomax (bivalirudin) is an intravenous (IV) bolus dose of 1.0 mg/kg followed by a 4-hour IV infusion at a rate of 2.5 mg/kg/h. After completion of the initial 4-hour infusion, an additional IV infusion of Angiomax may be initiated at a rate of 0.2 mg/kg/h for up to 20 hours if needed.
Route of Administration:
Intravenous
| Substance Class |
Protein
Created
by
admin
on
Edited
Tue Apr 01 18:11:06 GMT 2025
by
admin
on
Tue Apr 01 18:11:06 GMT 2025
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
8631NP8608
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C263
Created by
admin on Tue Apr 01 18:11:06 GMT 2025 , Edited by admin on Tue Apr 01 18:11:06 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
EF-17
Created by
admin on Tue Apr 01 18:11:06 GMT 2025 , Edited by admin on Tue Apr 01 18:11:06 GMT 2025
|
PRIMARY | |||
|
1191386-50-1
Created by
admin on Tue Apr 01 18:11:06 GMT 2025 , Edited by admin on Tue Apr 01 18:11:06 GMT 2025
|
PRIMARY | |||
|
300000044782
Created by
admin on Tue Apr 01 18:11:06 GMT 2025 , Edited by admin on Tue Apr 01 18:11:06 GMT 2025
|
PRIMARY | |||
|
8631NP8608
Created by
admin on Tue Apr 01 18:11:06 GMT 2025 , Edited by admin on Tue Apr 01 18:11:06 GMT 2025
|
PRIMARY | |||
|
C142963
Created by
admin on Tue Apr 01 18:11:06 GMT 2025 , Edited by admin on Tue Apr 01 18:11:06 GMT 2025
|
PRIMARY | |||
|
2380556
Created by
admin on Tue Apr 01 18:11:06 GMT 2025 , Edited by admin on Tue Apr 01 18:11:06 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
Agent Modifications
| Modification Process | Modification Role | Modification Type | Amount | Fragment Name | Fragment ID |
|---|---|---|---|---|---|
| SALT FORMATION |
|
Trifluoroacetic acid | E5R8Z4G708 |
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| Molecular Formula | CHEMICAL |
|
||||
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|